ArticleBMC infectious diseases2026
Factors associated with extended treatment duration in patients with drug-susceptible pulmonary tuberculosis: a prospective multicentre cohort study in South Korea.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundThe standard treatment for drug-susceptible tuberculosis (TB) is a 6-month short-course regimen; however, extended courses are often used in clinical practice. We aimed to identify factors associated with extended treatment in patients with drug-susceptible TB.
methodsWe conducted a prospective cohort study across 18 institutions in the Republic of Korea between July 2019 and June 2023 and enrolled patients with drug-susceptible TB who received the standard short-course regimen (isoniazid, rifampin, pyrazinamide, and ethambutol) and achieved treatment success at end of therapy. Patients were categorised by treatment duration: less than 200 days (standard treatment group) and more than 200 days (extended treatment group).
resultsOf 854 patients, 334 (39.1%) received extended treatment, and 520 (60.9%) received standard treatment. Baseline characteristics differed between groups (extended vs. standard): diabetes mellitus (31.4% vs. 22.5%; P = 0.01), a history of TB treatment (22.2% vs. 10.4%; P < 0.01), multilobar involvement (47.2% vs. 34.3%; P < 0.01), cavitary lesions on chest radiography (32.1% vs. 12.5%; P < 0.01), acid-fast bacillus (AFB) smear positivity (38.9% vs. 14.2%; P < 0.01), gastrointestinal adverse reactions (48.8% vs. 41.9%; P < 0.05), and treatment interruption > 7 days (11.1% vs. 3.1%; P < 0.01). In weighted logistic regression, previous TB (odds ratio [OR] 2.66, 95% confidence interval [CI] 1.67–4.25; P < 0.01), cavity (OR 2.56, 95% CI 1.63–4.02; P < 0.01), and AFB smear positivity (OR 4.06, 95% CI 2.73–6.04; P < 0.01) were significant baseline predictors of extended treatment. In the time-updated Cox analysis, older age (adjusted hazard ratio [aHR] 0.84, 95% CI 0.75–0.95; P < 0.01) and lower body mass index (aHR 0.95, 0.90–0.99; P = 0.02) were associated with a decreased likelihood of extended treatment. In contrast, cardiovascular disease (aHR 1.20, 1.06–1.36; P = 0.01), chronic lung disease (aHR 1.10, 1.01–1.19; P = 0.03), chronic kidney disease (aHR 1.15, 1.01–1.31; P = 0.03), malignancy (aHR 1.16, 1.03–1.30; P = 0.01), previous TB (aHR 1.09, 1.02–1.15; P = 0.01), and cavity (aHR 1.06, 1.01–1.12; P = 0.03) were positively associated with extended treatment. Among time-dependent factors, leucopenia (aHR 1.08, 1.02–1.16; P = 0.02) and 2-month culture positivity (aHR 1.09, 1.01–1.18; P = 0.03) were associated with an increased likelihood of extended treatment, whereas neuropathy (aHR 0.89, 0.80–0.98; P = 0.02) and nephrotoxicity (aHR 0.89, 0.80–0.98; P = 0.02) were associated with a decreased likelihood.
conclusionThis study identified patient and treatment factors associated with extended therapy for drug-susceptible TB in the Republic of Korea, underscoring the need for targeted interventions and strengthened monitoring to optimise treatment outcomes. CLINICAL TRIAL: This study was registered with the Clinical Research Information Service (CRIS), Republic of Korea (https://cris.nih.go.kr, registration number KCT0002594) on 1 November 2017.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.